The launch of Erelzi, Novartis’s FDA-approved etanercept (Enbrel) biosimilar, will be delayed at least another year as a patent fight with Amgen continues in US federal court, according to Richard Francis, global head of Novartis’s Sandoz generic division. Amgen is arguing in US federal court that its biologic Enbrel has patent protection until 2029. The lawsuit won’t reach a conclusion until 2018, Francis stated, adding that while the legal situation is frustrating he believes the company is “carving the landscape out as we go.”
Erelzi is the first biosimilar of etanercept to be approved by the FDA. It was approved on August 30, 2016, with an indication for the same indications as the reference drug Enbrel: rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. Amgen sued Novartis over patent issues before the FDA had even approved Erelzi.
Novartis and Amgen are also engaged in a separate legal case concerning Novartis’s Zarxio, a biosimilar of Amgen’s Neupogen (filgrastim), which was approved by the FDA in September 2015. This dispute revolves around whether biosimilar sponsors have to provide 180 days’ notice to the reference product’s company after FDA approval to begin marketing the biosimilar. Novartis is arguing that by making the biosimilar’s sponsor wait until FDA approval to notify the originator company of a launch, the court was creating “an exclusivity windfall” for the originator company that Congress did not intend in the Biologics Price Competition and Innovation Act. Novartis believes the biosimilar sponsor should be able to provide notice earlier in development and be able to launch the biosimilar soon after FDA approval. The Supreme Court recently agreed to consider that case.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.